Endonovo Therapeutics (ENDV)
(Delayed Data from OTC)
$0.00 USD
0.00 (-7.14%)
Updated Apr 19, 2024 02:52 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Endonovo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 0 | 0 | 0 | 0 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 0 | 0 | 0 |
Total Current Assets | NA | 0 | 0 | 0 | 0 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1 | 2 | 3 | 3 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 1 | 2 | 3 | 3 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 7 | 7 | 7 | 7 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 3 | 2 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 22 | 7 | 8 | 15 |
Total Current Liabilities | NA | 33 | 18 | 17 | 24 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 33 | 18 | 17 | 24 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 43 | 41 | 39 | 32 |
Retained Earnings | NA | -75 | -56 | -53 | -53 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -32 | -16 | -14 | -21 |
Total Liabilities & Shareholder's Equity | NA | 1 | 2 | 3 | 3 |
Total Common Equity | 0 | -32 | -16 | -14 | -21 |
Shares Outstanding | 318.70 | 219.70 | 74.50 | 24.50 | 1.10 |
Book Value Per Share | 0.00 | -0.15 | -0.21 | -0.59 | -18.64 |
Fiscal Year End for Endonovo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 0 | 0 | 0 |
Receivables | NA | NA | 0 | 0 | 0 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 0 |
Other Current Assets | NA | NA | 0 | 0 | 0 |
Total Current Assets | NA | NA | 0 | 0 | 0 |
Net Property & Equipment | NA | NA | 0 | 0 | 0 |
Investments & Advances | NA | NA | 0 | 0 | 0 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | NA | 1 | 1 | 1 |
Deposits & Other Assets | NA | NA | 0 | 0 | 0 |
Total Assets | NA | NA | 1 | 1 | 1 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 7 | 7 | 7 |
Accounts Payable | NA | NA | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | NA | 0 | 0 | 0 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | NA | 4 | 4 | 4 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | NA | 11 | 11 | 14 |
Total Current Liabilities | NA | NA | 24 | 23 | 25 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | NA | 24 | 23 | 26 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | NA | 0 | 0 | 0 |
Capital Surplus | NA | NA | 44 | 44 | 44 |
Retained Earnings | NA | NA | -67 | -66 | -68 |
Other Equity | NA | NA | 0 | 0 | 0 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | NA | -23 | -22 | -24 |
Total Liabilities & Shareholder's Equity | NA | NA | 1 | 1 | 1 |
Total Common Equity | 0 | 0 | -23 | -22 | -24 |
Shares Outstanding | 333.00 | 318.70 | 318.20 | 278.80 | 270.20 |
Book Value Per Share | 0.00 | 0.00 | -0.07 | -0.08 | -0.09 |